(Mapi Group) An ICON plc Company

Thank you to all our followers, @MapiGlobal will no longer be updated. Please follow us at @ICONplc ow.ly/LCZz30odUz3

@ICONplc's rare disease clinical trials have led 9 drugs to market for #rarediseases in the past 5 years. Watch #ICONplc's short video here to learn more in support of @eurordis' #ShowYourRare #RareDiseaseDay 2019 campaign ow.ly/3Rrm50mcfPs

There are over 6,000 #raredisease types. Learn more from #ICONplc @ICONplc this #RareDiseaseDay ow.ly/a7gG50lYy8s

Wishing you happy holidays and a wonderful New Year. Best wishes from all @ICONplc ow.ly/Gy0d30n2Chw

Overcome the challenges of #oncology #clinicaltrials with @ICONplc's strategic approach ow.ly/clDZ50iUIdj

@ICONplc expert, Dr. Andrew Roche, Ph.D., discusses overcoming challenges when developing #diabetes #clinicaltrials in this webinar ow.ly/pPGI50jNldl

Explore the key challenges of declining #researchanddevelopment (R&D) efficiency in this @ContractPharma article featuring ICON #thoughtleadership ow.ly/LVxM30mHOGY

Discover #bioanalyticalmethods that can be leveraged to add value in #earlyphase #clinicalstudies in @ICONplc's recent blog post ow.ly/qNiH50iXinW

Making smarter, more timely decisions in #earlyphase #clinicaldevelopmentprogrammes can be achieved by adopting an #adaptivedesign. Discover how @ICONplc can help here ow.ly/sE1c50j3MXu

@ICONplc has a team of experts who are dedicated to the #researchanddevelopment of #NASH #clinicaltrials. Learn how ICON has overcome common challenges in NASH trials by watching their recent webinar recording ow.ly/Edid30mlu9D

Estimates show that #COPD will become the third leading cause of death by 2030, according to @WHO. Learn about @ICONplc’s #clinicaltrial solutions for the life-threatening #lungdisease here ow.ly/wKKg50jtn1u

@ICONplc's laboratories’ testing capability and their clinical experience in more than 500 #oncologytrials makes them a trusted partner in your research. Learn more here ow.ly/CDWC50jtqly

‘Embracing #disruption for a new era in healthcare’ is the theme for this year’s Global @FT #Pharma & #Biotech Conference (London; 5-6 Nov). Request @ICONplc's 25% registration discount code today to signup to attend ow.ly/hT8Q30mnvT0

Discover how @ICONplc's experts met the first-patient-in goal for two non- #cysticfibrosis #bronchiectasis phase III #clinicalstudies ow.ly/NJPH50jtmKu

Over the past 3 years, ICON has conducted 24 #respiratory clinical studies, which included 874 #clinicaltrial sites globally & more than 400 experienced respiratory team members. Learn more about @ICONplc's integrated approach to #pulmonary trials ow.ly/yM8q50jtkMB

Approvals for #carttherapies are increasing & scaling up requires overcoming new challenges. Explore @ICONplc's potential solutions @ ow.ly/Xu3J50j3AUx

Learn how to enhance #patientoutcomes in #immunooncology #clinicaltrials with thoughtful planning & more treatment options in @ICONplc's white paper ow.ly/1WeO50jtprr

Discover @ICONplc's strategies for maintaining #clinicalsite relationships and enhancing #patientrecruitment in #IBD #clinicalstudies ow.ly/2T5150iUFjb

Explore @ICONplc's tailored solutions to #IBD #clinicaltrial #patientenrolment challenges in our phase 2a case study ow.ly/hYmd50iUupz

@ICONplc has been shortlisted for the @Medtech_Insight #Medtech18 In Vivo Award for "Best Medtech Partnership/Alliance", recognising their work with the @bostonsci RM team & how they've set a new benchmark in partnering activity to-date. Learn more: ow.ly/GUcq30lqYGE